Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2025 Jun;206(6):1743-1753.
doi: 10.1111/bjh.20100. Epub 2025 May 19.

The 'Stop TPO-RA in ITP Patients' study: Clinical and immune modulatory effects of romiplostim tapering

Vivianne S Nelson  1   2   3 , Sufia N Amini  1 , Tanja Netelenbos  1 , Marina S Kartachova  4 , Roger E G Schutgens  5 , Otto Visser  6 , Peter E Westerweel  7 , Jaap J Zwaginga  3   8 , Suzanne Hofstede-van Egmond  9 , Rick Kapur  2 , Masja de Haas  8 , Leendert Porcelijn  9 , Martin R Schipperus  8
Affiliations
Clinical Trial

The 'Stop TPO-RA in ITP Patients' study: Clinical and immune modulatory effects of romiplostim tapering

Vivianne S Nelson et al. Br J Haematol. 2025 Jun.

Abstract

Sustained remissions off-treatment (SROTs) after tapering of thrombopoietin receptor agonists (TPO-RAs) have been reported in 15%-50% of patients with immune thrombocytopenia (ITP). The STIP (Stop TPO-Receptor Agonist in ITP Patients) study is a prospective trial aimed to investigate the clinical effects of romiplostim tapering. Adult patients (22/40) with ITP ≥3 months received romiplostim for 1 year, were tapered and followed for 1 year. Anti-platelet antibodies (APAs), TPO levels and indium-111 platelet scintigraphy were assessed before, during and after romiplostim. Censored survival analysis showed that the probability of SROT at 1 year after tapering was 23.6% (95% confidence interval: 11.0%-50.5%). Patients with SROT had higher platelet levels on romiplostim (median: 332.5 vs. 84.5 × 109/L) and lower romiplostim doses at the start of tapering (median: 1.0 vs. 4.5 μg/kg) compared to those with a non-sustained response (NSR). APAs were detected in 8/25 patients at baseline, of which 5 showed a substantial decrease during romiplostim. The indium-111 scan revealed an improved platelet survival at the start of tapering for 50% of patients with SROT (2/4, missing n = 1) versus none with an NSR (0/14, missing n = 3). Overall, the STIP study demonstrated a probability of SROT of 23.6% in a diverse and largely chronic group of adult patients with ITP.

Keywords: anti‐platelet antibodies; immune thrombocytopenia; indium‐111 platelet scintigraphy; thrombopoietin receptor agonist.

PubMed Disclaimer

Similar articles

See all similar articles

References

REFERENCES

    1. Lambert MP, Gernsheimer TB. Clinical updates in adult immune thrombocytopenia. Blood. 2017;129(21):2829–2835.
    1. Audia S, Mahévas M, Nivet M, Ouandji S, Ciudad M, Bonnotte B. Immune thrombocytopenia: recent advances in pathogenesis and treatments. Hemasphere. 2021;5(6):e574.
    1. Provan D, Arnold DM, Bussel JB, Chong BH, Cooper N, Gernsheimer T, et al. Updated international consensus report on the investigation and management of primary immune thrombocytopenia. Blood Adv. 2019;3(22):3780–3817. https://doi.org/10.1182/bloodadvances.2019000812
    1. Malik A, Sayed AA, Han P, Tan MMH, Watt E, Constantinescu‐Bercu A, et al. The role of CD8+ T‐cell clones in immune thrombocytopenia. Blood. 2023;141(20):2417–2429. https://doi.org/10.1182/blood.2022018380
    1. Olsson B, Andersson PO, Jernås M, Jacobsson S, Carlsson B, Carlsson LM, et al. T‐cell‐mediated cytotoxicity toward platelets in chronic idiopathic thrombocytopenic purpura. Nat Med. 2003;9(9):1123–1124. https://doi.org/10.1038/nm921

MeSH terms

LinkOut - more resources